Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

A. I. Mourad, R. Gniadecki
doi: https://doi.org/10.1101/2020.07.13.20151340

Article Information

doi 
https://doi.org/10.1101/2020.07.13.20151340
History 
  • July 15, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. A. I. Mourad, BSc MD1,2 and
  2. R. Gniadecki, MD PhD DMSci1,*
  1. 1Division of Dermatology, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta
  2. 2University of Calgary Cumming School of Medicine, Division of Dermatology, Department of Medicine
  1. ↵*Corresponding Author:
    Robert Gniadecki, MD PhD DMSci, Email: gniadeck{at}ualberta.ca

  1. Conflicts of Interest: Dr. Gniadecki has received speaker’s honorarium from Mallinckrodt, Janssen, AbbVie, Novartis, and Leo Pharma, is on the advisory board for Mallinckrodt, Janssen, Amgen, AbbVie, Eli Lily, Sanofi, Novartis, and Leo Pharma. Dr. Gniadecki is an investigator in clinical trials for Janssen, Celgene, AbbVie, and Leo Pharma. Dr. Mourad has no conflicts of interest to declare.

Back to top
Posted July 15, 2020.
Download PDF
Data/Code
Email
Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis
A. I. Mourad, R. Gniadecki
medRxiv 2020.07.13.20151340; doi: https://doi.org/10.1101/2020.07.13.20151340
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area